| abstract |
IL-1 delta polypeptides and polynucleotides and methods for producing suchnpolypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizingnIL-1 delta polypeptides and polynucleotides in the design of protocols for the treatment ofnchronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatorynbowel disease, psoriasis), transplant rejection, graft versus host disease, infection, stroke, ischemia,nacute respiratory disease syndrome, restenosis, brain injury, AIDS, bone diseases (e.g.nosteoporosis), cancer (e.g. lymphoproliferative disorders), atherosclerosis, and Alzheimer's disease,namong others, and diagnostic assays for such conditions. |